Search Results - "Sato, Takami"

Refine Results
  1. 1

    Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma by Cheng, Hanyin, Chua, Vivian, Liao, Connie, Purwin, Timothy J, Terai, Mizue, Kageyama, Ken, Davies, Michael A, Sato, Takami, Aplin, Andrew E

    Published in Molecular cancer therapeutics (01-03-2017)
    “…Patients with metastatic uveal melanoma usually die within 1 year of diagnosis, emphasizing an urgent need to develop new treatment strategies. The liver is…”
    Get full text
    Journal Article
  2. 2

    Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy by Sato, Takami, Terai, Mizue, Tamura, Yutaka, Alexeev, Vitali, Mastrangelo, Michael J., Selvan, Senthamil R.

    Published in Immunologic research (01-12-2011)
    “…IL-10 is an immunomodulatory cytokine that is frequently upregulated in various types of cancer. The biological role of IL-10 in cancer is quite complex;…”
    Get full text
    Journal Article
  3. 3

    Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma by Cheng, Hanyin, Terai, Mizue, Kageyama, Ken, Ozaki, Shinji, McCue, Peter A, Sato, Takami, Aplin, Andrew E

    Published in Cancer research (Chicago, Ill.) (01-07-2015)
    “…Uveal melanoma patients with metastatic disease usually die within one year, emphasizing an urgent need to develop new treatment strategies for this cancer…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Expression of Tryptophan 2,3-Dioxygenase in Metastatic Uveal Melanoma by Terai, Mizue, Londin, Eric, Rochani, Ankit, Link, Emma, Lam, Bao, Kaushal, Gagan, Bhushan, Alok, Orloff, Marlana, Sato, Takami

    Published in Cancers (10-02-2020)
    “…Uveal melanoma (UM) is the most common primary eye malignancy in adults and up to 50% of patients subsequently develop systemic metastasis. Metastatic uveal…”
    Get full text
    Journal Article
  6. 6

    Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma by Chua, Vivian, Orloff, Marlana, Teh, Jessica LF, Sugase, Takahito, Liao, Connie, Purwin, Timothy J, Lam, Bao Q, Terai, Mizue, Ambrosini, Grazia, Carvajal, Richard D, Schwartz, Gary, Sato, Takami, Aplin, Andrew E

    Published in EMBO molecular medicine (01-02-2019)
    “…Alterations in transcriptional programs promote tumor development and progression and are targetable by bromodomain and extraterminal (BET) protein inhibitors…”
    Get full text
    Journal Article
  7. 7

    Development and optimization of orthotopic liver metastasis xenograft mouse models in uveal melanoma by Sugase, Takahito, Lam, Bao Q, Danielson, Meggie, Terai, Mizue, Aplin, Andrew E, Gutkind, J Silvio, Sato, Takami

    Published in Journal of translational medicine (20-05-2020)
    “…Patients with metastatic uveal melanoma (MUM) in the liver usually die within 1 year. The development of new treatments for MUM has been limited by the lack of…”
    Get full text
    Journal Article
  8. 8

    PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma by Javed, Asad, Arguello, David, Johnston, Curtis, Gatalica, Zoran, Terai, Mizue, Weight, Ryan M, Orloff, Marlana, Mastrangelo, Michael J, Sato, Takami

    Published in Immunotherapy (01-12-2017)
    “…To compare PD-L1 expression between metastatic uveal melanoma (MUM) and metastatic cutaneous melanoma (MCM). A total of 295 MCM and 78 MUM specimens were…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11

    Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis by Kageyama, Ken, Ohara, Masahiro, Saito, Kengo, Ozaki, Shinji, Terai, Mizue, Mastrangelo, Michael J, Fortina, Paolo, Aplin, Andrew E, Sato, Takami

    Published in Journal of translational medicine (23-06-2017)
    “…Metastatic uveal melanoma is a highly fatal disease; most patients die from their hepatic metastasis within 1 year. A major drawback in the development of new…”
    Get full text
    Journal Article
  12. 12

    Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival by Brody, Jonathan R., Costantino, Christina L., Berger, Adam C., Sato, Takami, Lisanti, Michael P., Yeo, Charles J., Emmons, Robert V., Witkiewicz, Agnieszka K.

    Published in Cell cycle (Georgetown, Tex.) (15-06-2009)
    “…The mechanism by which malignant melanoma (MM) cells survive in lymph nodes is poorly understood. One possible mechanism by which MM cells can escape immune…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Prognostic Values of G-Protein Mutations in Metastatic Uveal Melanoma by Terai, Mizue, Shimada, Ayako, Chervoneva, Inna, Hulse, Liam, Danielson, Meggie, Swensen, Jeff, Orloff, Marlana, Wedegaertner, Philip B, Benovic, Jeffrey L, Aplin, Andrew E, Sato, Takami

    Published in Cancers (17-11-2021)
    “…Uveal melanoma is the most common primary ocular malignancy in adults, characterized by gene mutations in G protein subunit alpha q ( ) and G protein subunit…”
    Get full text
    Journal Article
  15. 15

    Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients by Snook, Adam E, Baybutt, Trevor R, Xiang, Bo, Abraham, Tara S, Flickinger, Jr, John C, Hyslop, Terry, Zhan, Tingting, Kraft, Walter K, Sato, Takami, Waldman, Scott A

    Published in Journal for immunotherapy of cancer (23-04-2019)
    “…The colorectal cancer antigen GUCY2C exhibits unique split tolerance, evoking antigen-specific CD8 , but not CD4 , T-cell responses that deliver anti-tumor…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

    Integrin receptors on tumor cells facilitate NK cell‐mediated antibody‐dependent cytotoxicity by Anikeeva, Nadia, Steblyanko, Maria, Fayngerts, Svetlana, Kopylova, Natalya, Marshall, Deborah J., Powers, Gordon D., Sato, Takami, Campbell, Kerry S., Sykulev, Yuri

    Published in European journal of immunology (01-08-2014)
    “…NK cells that mediate ADCC play an important role in tumor‐specific immunity. We have examined factors limiting specific lysis of tumor cells by CD16.NK‐92…”
    Get full text
    Journal Article